Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025
It is often marketed as a collagen peptide or anti aging peptide. Both descriptions are incomplete
Advanced context: Researchers are developing hyaluronic acid-functionalized nanoparticle delivery (HA-KPV-NP) that dramatically improves oral efficacy
The convenient 2-Pack contains two separate 3ml vials
For GHK-Cu, the best-supported claims come from topical and wound-related evidence, while injectable and systemic claims need more rigorous human data [2], [3], [8]
doi:10.1016/S2213-8587(19)30066-X Zinman B, Bhosekar V, Busch R, et al